Tumor stroma as targets for cancer therapy

Pharmacology and Therapeutics

Volumn 137, Issue 2, 2013, Pages 200-215

  Zhang, Jing ^a,b   Liu, Jinsong ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer signaling; Cancer therapy; Cancer associated fibroblasts; Extracellular matrix; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CABOZANTINIB; CALVASCULIN; CARBOPLATIN; CELECOXIB; CILENGITIDE; CRIZOTINIB; DOCETAXEL; ETARACIZUMAB; FIBRONECTIN; INTERLEUKIN 1BETA; LAMININ; MARIMASTAT; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRINOMASTAT; RILOTUMUMAB; STROMAL CELL DERIVED FACTOR 1; TENASCIN; THROMBOSPONDIN 1; TIVANTINIB; TUMOR NECROSIS FACTOR ALPHA; UPAMOSTAT; UROKINASE; VOLOCIXIMAB;

ANGIOGENESIS; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL FUNCTION; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MUTATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID CANCER; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; FIBROBLASTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; STROMAL CELLS;

EID: 84872785096     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.10.003     Document Type: Review

References (202)

1. L. Albiges, M. Salem, B. Rini, and B. Escudier Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma Hematol Oncol Clin North Am 25 2011 813 833
2. C. Anderberg, H. Li, L. Fredriksson, J. Andrae, C. Betsholtz, and X. Li Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts Cancer Res 69 2009 369 378
3. S. Andersen, T. Donnem, S. Al-Saad, K. Al-Shibli, L.T. Busund, and R.M. Bremnes Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy J Thorac Oncol 4 2009 463 471
4. P.A. Andreasen, R. Egelund, and H.H. Petersen The plasminogen activation system in tumor growth, invasion, and metastasis Cell Mol Life Sci 57 2000 25 40
5. M. Augsten, C. Hagglof, E. Olsson, C. Stolz, P. Tsagozis, and T. Levchenko CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth Proc Natl Acad Sci U S A 106 2009 3414 3419
6. M. Augsten, C. Hagglof, C. Pena, and A. Ostman A digest on the role of the tumor microenvironment in gastrointestinal cancers Cancer Microenviron 3 2010 167 176
7. M. Balsamo, F. Scordamaglia, G. Pietra, C. Manzini, C. Cantoni, and M. Boitano Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity Proc Natl Acad Sci U S A 106 2009 20847 20852
8. V. Barry-Hamilton, R. Spangler, D. Marshall, S. McCauley, H.M. Rodriguez, and M. Oyasu Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat Med 16 2010 1009 1017
9. K.M. Bell-McGuinn, C.M. Matthews, S.N. Ho, M. Barve, L. Gilbert, and R.T. Penson A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer Gynecol Oncol 121 2011 273 279
10. A. Berkenblit, U.A. Matulonis, J.F. Kroener, B.J. Dezube, G.N. Lam, and L.C. Cuasay A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial Gynecol Oncol 99 2005 50 57
11. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, and K. Kim Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884
12. P.M. Biselli-Chicote, A.R. Oliveira, E.C. Pavarino, and E.M. Goloni-Bertollo VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer J Cancer Res Clin Oncol 138 2012 363 370
13. M.J. Bissell, and D. Radisky Putting tumours in context Nat Rev Cancer 1 2001 46 54
14. C. Bisson, S. Blacher, M. Polette, J.F. Blanc, F. Kebers, and J. Desreux Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells Int J Cancer 105 2003 7 13
15. U. Bogdahn, P. Hau, G. Stockhammer, N.K. Venkataramana, A.K. Mahapatra, and A. Suri Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro Oncol 13 2011 132 142
16. D. Bourboulia, and W.G. Stetler-Stevenson Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion Semin Cancer Biol 20 2010 161 168
17. R.M. Bremnes, T. Donnem, S. Al-Saad, K. Al-Shibli, S. Andersen, and R. Sirera The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer J Thorac Oncol 6 2011 209 217
18. M.A. Buerkle, S.A. Pahernik, A. Sutter, A. Jonczyk, K. Messmer, and M. Dellian Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo Br J Cancer 86 2002 788 795
19. S. Cannito, E. Novo, L.V. di Bonzo, C. Busletta, S. Colombatto, and M. Parola Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease Antioxid Redox Signal 12 2010 1383 1430
20. R. Cao, A. Eriksson, H. Kubo, K. Alitalo, Y. Cao, and J. Thyberg Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability Circ Res 94 2004 664 670
21. A.R. Cardones, T. Murakami, and S.T. Hwang CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin Cancer Res 63 2003 6751 6757
22. A. Carter Integrins as target: first phase III trial launches, but questions remain J Natl Cancer Inst 102 2010 675 677
23. M.C. Cathcart, K.J. O'Byrne, J.V. Reynolds, J. O'Sullivan, and G.P. Pidgeon COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention Biochim Biophys Acta 1825 2012 49 63
24. V.J. Christiansen, K.W. Jackson, K.N. Lee, and P.A. McKee Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV Arch Biochem Biophys 457 2007 177 186
25. C. Chuaysri, P. Thuwajit, A. Paupairoj, S. Chau-In, T. Suthiphongchai, and C. Thuwajit Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma Oncol Rep 21 2009 957 969
26. P. Cirri, and P. Chiarugi Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression Cancer Metastasis Rev 31 2012 195 208
27. E.C. Connolly, E.F. Saunier, D. Quigley, M.T. Luu, A. De Sapio, and B. Hann Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761 Cancer Res 71 2011 2339 2349
28. V.J. Coulson-Thomas, T.F. Gesteira, Y.M. Coulson-Thomas, C.M. Vicente, I.L. Tersariol, and H.B. Nader Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation Exp Cell Res 316 2010 3207 3226
29. Y. Crawford, I. Kasman, L. Yu, C. Zhong, X. Wu, and Z. Modrusan PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 15 2009 21 34
30. K. Dass, A. Ahmad, A.S. Azmi, S.H. Sarkar, and F.H. Sarkar Evolving role of uPA/uPAR system in human cancers Cancer Treat Rev 34 2008 122 136
31. J.F. DiPersio, I.N. Micallef, P.J. Stiff, B.J. Bolwell, R.T. Maziarz, and E. Jacobsen Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma J Clin Oncol 27 2009 4767 4773
32. J.F. DiPersio, E.A. Stadtmauer, A. Nademanee, I.N. Micallef, P.J. Stiff, and J.L. Kaufman Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma Blood 113 2009 5720 5726
33. N.C. Direkze, K. Hodivala-Dilke, R. Jeffery, T. Hunt, R. Poulsom, and D. Oukrif Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts Cancer Res 64 2004 8492 8495
34. J. Dong, J. Grunstein, M. Tejada, F. Peale, G. Frantz, and W.C. Liang VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis EMBO J 23 2004 2800 2810
35. D.G. Duda, S.V. Kozin, N.D. Kirkpatrick, L. Xu, D. Fukumura, and R.K. Jain CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17 2011 2074 2080
36. M.J. Duffy The urokinase plasminogen activator system: role in malignancy Curr Pharm Des 10 2004 39 49
37. S. Duriseti, D.H. Goetz, D.R. Hostetter, A.M. LeBeau, Y. Wei, and C.S. Craik Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration J Biol Chem 285 2010 26878 26888
38. S.G. Eckhardt, J. Rizzo, K.R. Sweeney, G. Cropp, S.D. Baker, and M.A. Kraynak Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors J Clin Oncol 17 1999 1095 1104
39. R.A. El-Awady, E.M. Saleh, M. Ezz, and A.M. Elsayed Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells Toxicol Appl Pharmacol 255 2011 271 286
40. N. Erez, M. Truitt, P. Olson, S.T. Arron, and D. Hanahan Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner Cancer Cell 17 2010 135 147
41. H. Fiegl, S. Millinger, G. Goebel, E. Muller-Holzner, C. Marth, and P.W. Laird Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer Cancer Res 66 2006 29 33
42. J. Fuxe, S. Tabruyn, K. Colton, H. Zaid, A. Adams, and P. Baluk Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation Am J Pathol 178 2011 2897 2909
43. C. Gaggioli, S. Hooper, C. Hidalgo-Carcedo, R. Grosse, J.F. Marshall, and K. Harrington Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells Nat Cell Biol 9 2007 1392 1400
44. A. Gaya, and V. Tse A preclinical and clinical review of aflibercept for the management of cancer Cancer Treat Rev 38 2012 484 493
45. P.A. Gerber, A. Hippe, B.A. Buhren, A. Muller, and B. Homey Chemokines in tumor-associated angiogenesis Biol Chem 390 2009 1213 1223
46. S.A. Ghamande, M.H. Silverman, W. Huh, K. Behbakht, G. Ball, and L. Cuasay A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer Gynecol Oncol 111 2008 89 94
47. G. Giannelli, E. Fransvea, F. Marinosci, C. Bergamini, S. Colucci, and O. Schiraldi Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin Am J Pathol 161 2002 183 193
48. G. Gokalp, U. Topal, N. Yildirim, and S. Tolunay Malignant spiculated breast masses: dynamic contrast enhanced MR (DCE-MR) imaging enhancement characteristics and histopathological correlation Eur J Radiol 81 2012 203 208
49. J.W. Goldman, I. Laux, F. Chai, R.E. Savage, D. Ferrari, and E.G. Garmey Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib Cancer 2012 10.1002/cncr.27575
50. L.J. Goldstein Experience in phase I trials and an upcoming phase Ii study with uPA inhibitors in metastatic breast cancer Breast Care (Basel) 3 2008 25 28
51. T.A. Gonda, A. Varro, T.C. Wang, and B. Tycko Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol 21 2010 2 10
52. H.J. Groen, H. Sietsma, A. Vincent, M.M. Hochstenbag, J.W. van Putten, and A. van den Berg Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study J Clin Oncol 29 2011 4320 4326
53. H.G. Hagedorn, B.E. Bachmeier, and A.G. Nerlich Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-β in invasive carcinomas Int J Oncol 18 2001 669 681
54. M.A. Haniffa, X.N. Wang, U. Holtick, M. Rae, J.D. Isaacs, and A.M. Dickinson Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells J Immunol 179 2007 1595 1604
55. J.A. Hanson, J.W. Gillespie, A. Grover, M.A. Tangrea, R.F. Chuaqui, and M.R. Emmert-Buck Gene promoter methylation in prostate tumor-associated stromal cells J Natl Cancer Inst 98 2006 255 261
56. T.N. Hartmann, V. Grabovsky, R. Pasvolsky, Z. Shulman, E.C. Buss, and A. Spiegel A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells J Leukoc Biol 84 2008 1130 1140
57. P. Hau, P. Jachimczak, J. Schlaier, and U. Bogdahn TGF-β2 signaling in high-grade gliomas Curr Pharm Biotechnol 12 2011 2150 2157
58. D. Hauzenberger, P. Olivier, D. Gundersen, and C. Ruegg Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin Eur J Immunol 29 1999 1435 1447
59. L.R. Henry, H.O. Lee, J.S. Lee, A. Klein-Szanto, P. Watts, and E.A. Ross Clinical implications of fibroblast activation protein in patients with colon cancer Clin Cancer Res 13 2007 1736 1741
60. K.J. Heppner, L.M. Matrisian, R.A. Jensen, and W.H. Rodgers Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response Am J Pathol 149 1996 273 282
61. P. Hersey, J. Sosman, S. O'Day, J. Richards, A. Bedikian, and R. Gonzalez A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma Cancer 116 2010 1526 1534
62. H. Hirte, I.B. Vergote, J.R. Jeffrey, R.N. Grimshaw, S. Coppieters, and B. Schwartz A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study Gynecol Oncol 102 2006 300 308
63. S. Hiscox, P. Barrett-Lee, and R.I. Nicholson Therapeutic targeting of tumor-stroma interactions Expert Opin Ther Targets 15 2011 609 621
64. R.D. Hofheinz, S.E. al-Batran, F. Hartmann, G. Hartung, D. Jager, and C. Renner Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer Onkologie 26 2003 44 48
65. M. Hu, G. Peluffo, H. Chen, R. Gelman, S. Schnitt, and K. Polyak Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast Proc Natl Acad Sci U S A 106 2009 3372 3377
66. M. Hu, J. Yao, L. Cai, K.E. Bachman, F. van den Brule, and V. Velculescu Distinct epigenetic changes in the stromal cells of breast cancers Nat Genet 37 2005 899 905
67. X. Hua, L. Yu, X. Huang, Z. Liao, and Q. Xian Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma Diagn Pathol 6 2011 111
68. S. Huang, R. Fang, J. Xu, S. Qiu, H. Zhang, and J. Du Evaluation of the tumor targeting of a FAPalpha-based doxorubicin prodrug J Drug Target 19 2011 487 496
69. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
70. H. Ijichi, A. Chytil, A.E. Gorska, M.E. Aakre, B. Bierie, and M. Tada Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma J Clin Invest 121 2011 4106 4117
71. Y. Itoh, T. Joh, S. Tanida, M. Sasaki, H. Kataoka, and K. Itoh IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells Cytokine 29 2005 275 282
72. K. Itoh, T. Shiozawa, S. Ohira, S. Shiohara, and I. Konishi Correlation between MRI and histopathologic findings in stage I cervical carcinomas: influence of stromal desmoplastic reaction Int J Gynecol Cancer 16 2006 610 614
73. F. Jaschinski, T. Rothhammer, P. Jachimczak, C. Seitz, A. Schneider, and K.H. Schlingensiepen The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2 Curr Pharm Biotechnol 12 2011 2203 2213
74. M. Jechlinger, A. Sommer, R. Moriggl, P. Seither, N. Kraut, and P. Capodiecci Autocrine PDGFR signaling promotes mammary cancer metastasis J Clin Invest 116 2006 1561 1570
75. S. Jelisavac-Cosic, M. Sirotkovic-Skerlev, A. Kulic, J. Jakic-Razumovic, Z. Kovac, and D. Vrbanec Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study Tumori 97 2011 532 539
76. L. Jiang, T.A. Gonda, M.V. Gamble, M. Salas, V. Seshan, and S. Tu Global hypomethylation of genomic DNA in cancer-associated myofibroblasts Cancer Res 68 2008 9900 9908
77. D.W. Jung, Z.M. Che, J. Kim, K. Kim, K.Y. Kim, and D. Williams Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7 Int J Cancer 127 2010 332 344
78. M. Kajita, Y. Itoh, T. Chiba, H. Mori, A. Okada, and H. Kinoh Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration J Cell Biol 153 2001 893 904
79. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 2006 392 401
80. O. Kargiotis, C. Chetty, V. Gogineni, C.S. Gondi, S.M. Pulukuri, and A.P. Kyritsis uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo Int J Oncol 33 2008 937 947
81. H. Katoh, K. Hosono, Y. Ito, T. Suzuki, Y. Ogawa, and H. Kubo COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems Am J Pathol 176 2010 1469 1483
82. T. Kelly Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy Drug Resist Updat 8 2005 51 58
83. P.A. Kenny, G.Y. Lee, and M.J. Bissell Targeting the tumor microenvironment Front Biosci 12 2007 3468 3474
84. S.Y. Kim, C.H. Lee, B.V. Midura, C. Yeung, A. Mendoza, and S.H. Hong Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases Clin Exp Metastasis 25 2008 201 211
85. Y.J. Ko, E.J. Small, F. Kabbinavar, A. Chachoua, S. Taneja, and D. Reese A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer Clin Cancer Res 7 2001 800 805
86. F. Koga, S. Tsutsumi, and L.M. Neckers Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells Cell Cycle 6 2007 1393 1402
87. Y. Kojima, A. Acar, E.N. Eaton, K.T. Mellody, C. Scheel, and I. Ben-Porath Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts Proc Natl Acad Sci U S A 107 2010 20009 20014
88. L. Kolacna, J. Bakesova, F. Varga, E. Kostakova, L. Planka, and A. Necas Biochemical and biophysical aspects of collagen nanostructure in the extracellular matrix Physiol Res 56 Suppl. 1 2007 S51 S60
89. S.A. Kono, L.E. Heasley, R.C. Doebele, and D.R. Camidge Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer Curr Cancer Drug Targets 12 2012 107 123
90. Y. Koshida, M. Kuranami, and M. Watanabe Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor J Surg Res 134 2006 270 277
91. M. Kraman, P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, and J.O. Jones Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha Science 330 2010 827 830
92. S. Krishnaswamy, R. Kanteti, J.S. Duke-Cohan, S. Loganathan, W. Liu, and P.C. Ma Ethnic differences and functional analysis of MET mutations in lung cancer Clin Cancer Res 15 2009 5714 5723
93. Y. Krupitskaya, and H.A. Wakelee Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Curr Opin Investig Drugs 10 2009 597 605
94. K. Kurose, K. Gilley, S. Matsumoto, P.H. Watson, X.P. Zhou, and C. Eng Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas Nat Genet 32 2002 355 357
95. D. Lafkas, G. Trimis, A.G. Papavassiliou, and H. Kiaris P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy Int J Cancer 123 2008 967 971
96. A.M. LeBeau, W.N. Brennen, S. Aggarwal, and S.R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol Cancer Ther 8 2009 1378 1386
97. H.O. Lee, S.R. Mullins, J. Franco-Barraza, M. Valianou, E. Cukierman, and J.D. Cheng FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells BMC Cancer 11 2011 245
98. F. Legge, A. Paglia, M. D'Asta, G. Fuoco, G. Scambia, and G. Ferrandina Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients BMC Cancer 11 2011 214
99. X. Li, M. Tjwa, L. Moons, P. Fons, A. Noel, and A. Ny Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors J Clin Invest 115 2005 118 127
100. M.I. Lin, and W.C. Sessa Antiangiogenic therapy: creating a unique "window" of opportunity Cancer Cell 6 2004 529 531
101. R. Liu, H. Li, L. Liu, J. Yu, and X. Ren Fibroblast activation protein: a potential therapeutic target in cancer Cancer Biol Ther 13 2012 123 129
102. J.D. Loike, L. Cao, S. Budhu, S. Hoffman, and S.C. Silverstein Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins J Immunol 166 2001 7534 7542
103. G. Lorusso, and C. Ruegg The tumor microenvironment and its contribution to tumor evolution toward metastasis Histochem Cell Biol 130 2008 1091 1103
104. G. Maity, P.R. Choudhury, T. Sen, K.K. Ganguly, H. Sil, and A. Chatterjee Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity Tumour Biol 32 2011 129 138
105. R.B. Maksym, M. Tarnowski, K. Grymula, J. Tarnowska, M. Wysoczynski, and R. Liu The role of stromal-derived factor-1-CXCR7 axis in development and cancer Eur J Pharmacol 625 2009 31 40
106. A.M. Manicone, and J.K. McGuire Matrix metalloproteinases as modulators of inflammation Semin Cell Dev Biol 19 2008 34 41
107. J. Mann, F. Oakley, F. Akiboye, A. Elsharkawy, A.W. Thorne, and D.A. Mann Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis Cell Death Differ 14 2007 275 285
108. J. Massague TGFβ in Cancer Cell 134 2008 215 230
109. K. Matsumoto, and T. Nakamura Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions Int J Cancer 119 2006 477 483
110. G. Maulik, T. Kijima, P.C. Ma, S.K. Ghosh, J. Lin, and G.I. Shapiro Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer Clin Cancer Res 8 2002 620 627
111. A. Mazzocca, E. Fransvea, F. Dituri, L. Lupo, S. Antonaci, and G. Giannelli Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma Hepatology 51 2010 523 534
112. A. Mazzocca, E. Fransvea, G. Lavezzari, S. Antonaci, and G. Giannelli Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation Hepatology 50 2009 1140 1151
113. D.G. Menter, R.L. Schilsky, and R.N. DuBois Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward Clin Cancer Res 16 2010 1384 1390
114. J.E. Meyer, C. Brocks, H. Graefe, C. Mala, N. Thans, and M. Burgle The oral serine protease inhibitor WX-671 - first experience in patients with advanced head and neck carcinoma Breast Care (Basel) 3 2008 20 24
115. L. Mueller, F.A. Goumas, M. Affeldt, S. Sandtner, U.M. Gehling, and S. Brilloff Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment Am J Pathol 171 2007 1608 1618
116. L. Mueller, L.V. Seggern, J. Schumacher, F. Goumas, C. Wilms, and F. Braun TNF-alpha similarly induces IL-6 and MCP-1 in fibroblasts from colorectal liver metastases and normal liver fibroblasts Biochem Biophys Res Commun 397 2010 586 591
117. A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, and M.E. Buchanan Involvement of chemokine receptors in breast cancer metastasis Nature 410 2001 50 56
118. L.B. Nabors, T. Mikkelsen, M.E. Hegi, X. Ye, T. Batchelor, and G. Lesser A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) Cancer 2012 10.1002/cncr.27585
119. J.S. Nam, M. Terabe, M. Mamura, M.J. Kang, H. Chae, and C. Stuelten An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments Cancer Res 68 2008 3835 3843
120. K. Narra, S.R. Mullins, H.O. Lee, B. Strzemkowski-Brun, K. Magalong, and V.J. Christiansen Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer Cancer Biol Ther 6 2007 1691 1699
121. R. Navab, J. Liu, I. Seiden-Long, W. Shih, M. Li, and B. Bandarchi Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells Neoplasia 11 2009 1292 1300
122. M.R. Nazareth, L. Broderick, M.R. Simpson-Abelson, R.J. Kelleher Jr., S.J. Yokota, and R.B. Bankert Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells J Immunol 178 2007 5552 5562
123. K. Nishimura, K. Matsumiya, H. Miura, A. Tsujimura, N. Nonomura, and K. Matsumoto Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells Int J Androl 26 2003 175 179
124. H. Nystrom, P. Naredi, L. Hafstrom, and M. Sund Type IV collagen as a tumour marker for colorectal liver metastases Eur J Surg Oncol 37 2011 611 617
125. O.O. Ogunwobi, and C. Liu Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways Clin Exp Metastasis 28 2011 721 731
126. Y. Ohta, V. Shridhar, R.K. Bright, G.P. Kalemkerian, W. Du, and M. Carbone VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours Br J Cancer 81 1999 54 61
127. A.F. Olumi, G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium Cancer Res 59 1999 5002 5011
128. A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, and R. Naeem Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 2005 335 348
129. E. Ostermann, P. Garin-Chesa, K.H. Heider, M. Kalat, H. Lamche, and C. Puri Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts Clin Cancer Res 14 2008 4584 4592
130. A. Ostman, and M. Augsten Cancer-associated fibroblasts and tumor growth - bystanders turning into key players Curr Opin Genet Dev 19 2009 67 73
131. S. Paget The distribution of secondary growths in cancer of the breast Cancer Metastasis Rev 8 1989 98 101
132. A. Patocs, L. Zhang, Y. Xu, F. Weber, T. Caldes, and G.L. Mutter Breast-cancer stromal cells with TP53 mutations and nodal metastases N Engl J Med 357 2007 2543 2551
133. J. Paulsson, T. Sjoblom, P. Micke, F. Ponten, G. Landberg, and C.H. Heldin Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer Am J Pathol 175 2009 334 341
134. O.W. Petersen, H.L. Nielsen, T. Gudjonsson, R. Villadsen, F. Rank, and E. Niebuhr Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma Am J Pathol 162 2003 391 402
135. A.E. Place, S. Jin Huh, and K. Polyak The microenvironment in breast cancer progression: biology and implications for treatment Breast Cancer Res 13 2011 227
136. J.A. Posey, M.B. Khazaeli, A. DelGrosso, M.N. Saleh, C.Y. Lin, and W. Huse A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer Cancer Biother Radiopharm 16 2001 125 132
137. M. Provencal, N. Berger-Thibault, D. Labbe, R. Veitch, D. Boivin, and G.E. Rivard Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells J Neurooncol 97 2010 365 372
138. C. Pyke, P. Kristensen, E. Ralfkiaer, J. Grondahl-Hansen, J. Eriksen, and F. Blasi Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas Am J Pathol 138 1991 1059 1067
139. W. Qiu, M. Hu, A. Sridhar, K. Opeskin, S. Fox, and M. Shipitsin No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas Nat Genet 40 2008 650 655
140. D. Radisky, J. Muschler, and M.J. Bissell Order and disorder: the role of extracellular matrix in epithelial cancer Cancer Invest 20 2002 139 153
141. E.S. Radisky, and D.C. Radisky Stromal induction of breast cancer: inflammation and invasion Rev Endocr Metab Disord 8 2007 279 287
142. K. Rasanen, and A. Vaheri Activation of fibroblasts in cancer stroma Exp Cell Res 316 2010 2713 2722
143. A.S. Ribeiro, A. Albergaria, B. Sousa, A.L. Correia, M. Bracke, and R. Seruca Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells Oncogene 29 2010 392 402
144. A.D. Ricart, A.W. Tolcher, G. Liu, K. Holen, G. Schwartz, and M. Albertini Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study Clin Cancer Res 14 2008 7924 7929
145. A.M. Richardson, K. Woodson, Y. Wang, J. Rodriguez-Canales, H.S. Erickson, and M.A. Tangrea Global expression analysis of prostate cancer-associated stroma and epithelia Diagn Mol Pathol 16 2007 189 197
146. J. Rodriguez-Canales, J.C. Hanson, M.A. Tangrea, H.S. Erickson, P.S. Albert, and B.S. Wallis Identification of a unique epigenetic sub-microenvironment in prostate cancer J Pathol 211 2007 410 419
147. L. Ronnov-Jessen, and O.W. Petersen Induction of alpha-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia Lab Invest 68 1993 696 707
148. L. Ronnov-Jessen, O.W. Petersen, V.E. Koteliansky, and M.J. Bissell The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells J Clin Invest 95 1995 859 873
149. M.J. Ronty, S.K. Leivonen, B. Hinz, A. Rachlin, C.A. Otey, and V.M. Kahari Isoform-specific regulation of the actin-organizing protein palladin during TGF-β1-induced myofibroblast differentiation J Invest Dermatol 126 2006 2387 2396
150. P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
151. S. Saigusa, Y. Toiyama, K. Tanaka, T. Yokoe, Y. Okugawa, and H. Fujikawa Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy Int J Oncol 38 2011 655 663
152. S. Saji, M. Hirose, and M. Toi Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer Breast Cancer 11 2004 129 133
153. A.V. Salnikov, N.E. Heldin, L.B. Stuhr, H. Wiig, H. Gerber, and R.K. Reed Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma Int J Cancer 119 2006 2795 2802
154. N. Sato, N. Maehara, and M. Goggins Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts Cancer Res 64 2004 6950 6956
155. I.G. Schauer, A.K. Sood, S. Mok, and J. Liu Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of
156. K.H. Schlingensiepen, F. Jaschinski, S.A. Lang, C. Moser, E.K. Geissler, and H.J. Schlitt Transforming growth factor-β2 gene silencing with trabedersen (AP 12009) in pancreatic cancer Cancer Sci 102 2011 1193 1200
157. M. Schmitt, N. Harbeck, N. Brunner, F. Janicke, C. Meisner, and B. Muhlenweg Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Expert Rev Mol Diagn 11 2011 617 634
158. M. Schmitt, K. Mengele, R. Napieralski, V. Magdolen, U. Reuning, and A. Gkazepis Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Expert Rev Mol Diagn 10 2010 1051 1067
159. A.M. Scott, G. Wiseman, S. Welt, A. Adjei, F.T. Lee, and W. Hopkins A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer Clin Cancer Res 9 2003 1639 1647
160. G.D. Shah, N. Loizos, H. Youssoufian, J.D. Schwartz, and E.K. Rowinsky Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha Cancer 116 2010 1018 1026
161. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
162. T. Silzle, M. Kreutz, M.A. Dobler, G. Brockhoff, R. Knuechel, and L.A. Kunz-Schughart Tumor-associated fibroblasts recruit blood monocytes into tumor tissue Eur J Immunol 33 2003 1311 1320
163. T. Silzle, G.J. Randolph, M. Kreutz, and L.A. Kunz-Schughart The fibroblast: sentinel cell and local immune modulator in tumor tissue Int J Cancer 108 2004 173 180
164. C.F. Singer, N. Kronsteiner, E. Marton, M. Kubista, K.J. Cullen, and K. Hirtenlehner MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions Breast Cancer Res Treat 72 2002 69 77
165. R.K. Singh, and B.L. Lokeshwar The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth Cancer Res 71 2011 3268 3277
166. S. Singh, S.K. Srivastava, A. Bhardwaj, L.B. Owen, and A.P. Singh CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy Br J Cancer 103 2010 1671 1679
167. B. Sis, S. Sarioglu, S. Sokmen, M. Sakar, A. Kupelioglu, and M. Fuzun Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma J Clin Pathol 58 2005 32 38
168. M.C. Smith, K.E. Luker, J.R. Garbow, J.L. Prior, E. Jackson, and D. Piwnica-Worms CXCR4 regulates growth of both primary and metastatic breast cancer Cancer Res 64 2004 8604 8612
169. G.A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, and H. Archibald Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 Proc Natl Acad Sci U S A 103 2006 2316 2321
170. J.W. Song, S.P. Cavnar, A.C. Walker, K.E. Luker, M. Gupta, and Y.C. Tung Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells PLoS One 4 2009 e5756
171. M. Sonnenberg, H. van der Kuip, S. Haubeis, P. Fritz, W. Schroth, and G. Friedel Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast BMC Cancer 8 2008 364
172. J.A. Sparano, P. Bernardo, P. Stephenson, W.J. Gradishar, J.N. Ingle, and S. Zucker Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196 J Clin Oncol 22 2004 4683 4690
173. E. Steiner, K. Pollow, D. Hasenclever, W. Schormann, M. Hermes, and M. Schmidt Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer Gynecol Oncol 108 2008 569 576
174. M.T. Story, K.A. Hopp, and D.A. Meier Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells Prostate 28 1996 219 226
175. C.H. Stuelten, J.I. Busch, B. Tang, K.C. Flanders, A. Oshima, and E. Sutton Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-β mediated mechanism in a mouse xenograft model of breast cancer PLoS One 5 2010 e9832
176. J. Subramanian, D. Morgensztern, and R. Govindan Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Lung Cancer 11 2010 311 319
177. H. Sugimoto, T.M. Mundel, M.W. Kieran, and R. Kalluri Identification of fibroblast heterogeneity in the tumor microenvironment Cancer Biol Ther 5 2006 1640 1646
178. T. Sumida, Y. Kitadai, K. Shinagawa, M. Tanaka, M. Kodama, and M. Ohnishi Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model Int J Cancer 128 2011 2050 2062
179. H. Tamamura, A. Hori, N. Kanzaki, K. Hiramatsu, M. Mizumoto, and H. Nakashima T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer FEBS Lett 550 2003 79 83
180. K. Taniwaki, H. Fukamachi, K. Komori, Y. Ohtake, T. Nonaka, and T. Sakamoto Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice Cancer Res 67 2007 4311 4319
181. H. Terada, T. Urano, and H. Konno Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer Eur Surg Res 37 2005 166 172
182. V.J. Thannickal, D.Y. Lee, E.S. White, Z. Cui, J.M. Larios, and R. Chacon Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase J Biol Chem 278 2003 12384 12389
183. Y. Toiyama, H. Yasuda, S. Saigusa, K. Matushita, H. Fujikawa, and K. Tanaka Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer Int J Cancer 130 2012 2912 2921
184. M. Tokunou, T. Niki, K. Eguchi, S. Iba, H. Tsuda, and T. Yamada c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma Am J Pathol 158 2001 1451 1463
185. A.J. Trimboli, C.Z. Cantemir-Stone, F. Li, J.A. Wallace, A. Merchant, and N. Creasap Pten in stromal fibroblasts suppresses mammary epithelial tumours Nature 461 2009 1084 1091
186. T. Tsujino, I. Seshimo, H. Yamamoto, C.Y. Ngan, K. Ezumi, and I. Takemasa Stromal myofibroblasts predict disease recurrence for colorectal cancer Clin Cancer Res 13 2007 2082 2090
187. H. Tuhkanen, M. Anttila, V.M. Kosma, S. Heinonen, M. Juhola, and S. Helisalmi Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas Int J Cancer 119 2006 1345 1353
188. S.W. Tyan, W.H. Kuo, C.K. Huang, C.C. Pan, J.Y. Shew, and K.J. Chang Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis PLoS One 6 2011 e15313
189. T.S. Tzai, C.I. Lin, A.L. Shiau, and C.L. Wu Antisense oligonucleotide specific for transforming growth factor-β1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer Anticancer Res 18 1998 1585 1589
190. G. Untergasser, R. Gander, C. Lilg, G. Lepperdinger, E. Plas, and P. Berger Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation Mech Ageing Dev 126 2005 59 69
191. F. van Zijl, M. Mair, A. Csiszar, D. Schneller, G. Zulehner, and H. Huber Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge Oncogene 28 2009 4022 4033
192. H. Verbeke, S. Struyf, G. Laureys, and J. Van Damme The expression and role of CXC chemokines in colorectal cancer Cytokine Growth Factor Rev 22 2011 345 358
193. K. Walter, N. Omura, S.M. Hong, M. Griffith, and M. Goggins Pancreatic cancer associated fibroblasts display normal allelotypes Cancer Biol Ther 7 2008 882 888
194. Z. Wang, A. Ahmad, Y. Li, D. Kong, A.S. Azmi, and S. Banerjee Emerging roles of PDGF-D signaling pathway in tumor development and progression Biochim Biophys Acta 1806 2010 122 130
195. J. Wang, Y. Shiozawa, Y. Wang, Y. Jung, K.J. Pienta, and R. Mehra The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer J Biol Chem 283 2008 4283 4294
196. F. Weber, Y. Xu, L. Zhang, A. Patocs, L. Shen, and P. Platzer Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma JAMA 297 2007 187 195
197. D.L. Worthley, A.S. Giraud, and T.C. Wang Stromal fibroblasts in digestive cancer Cancer Microenviron 3 2010 117 125
198. Q. Xiao, and G. Ge Lysyl oxidase, extracellular matrix remodeling and cancer metastasis Cancer Microenviron 2012 10.1007/s12307-012-0105-z
199. G. Xouri, and S. Christian Origin and function of tumor stroma fibroblasts Semin Cell Dev Biol 21 2010 40 46
200. G. Yang, D.G. Rosen, Z. Zhang, R.C. Bast Jr., G.B. Mills, and J.A. Colacino The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis Proc Natl Acad Sci U S A 103 2006 16472 16477
201. Q. Yu, and I. Stamenkovic Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis Genes Dev 14 2000 163 176
202. E.M. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, and R. Kalluri Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts Cancer Res 67 2007 10123 10128